Scientists probe the hidden types of severe childhood asthma
NCT ID NCT04680117
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study looked at 54 children with severe asthma to better understand the different biological features (endotypes) of the disease. Researchers collected blood, saliva, and nasal samples, along with lung samples from bronchoscopies, to analyze immune cells, metabolism, and microbes. The goal was to identify distinct subtypes of severe asthma in children aged 0 to 12 years, which could eventually lead to more tailored treatments.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this research could help doctors better understand different types of severe asthma in children, leading to more personalized treatments in the future.
- What could go wrong
- This is an observational study, not a treatment trial. It aims to gather information, so there is no direct benefit to participants. The findings may not immediately change clinical practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
54 people
The number who actually took part.
- Started
-
Jun 2021
- Finished
-
Apr 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
Up to 12 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Patient Inclusion Criteria: * Minors aged 0 to 6 years or 6 to 12 years, hospitalized for assessment of Severe Asthma * Minors need with his follow-up an bronchial endoscopy with realization of LBA and biopsies of bronchial mucosa * Social insurance affiliation, except AME * Parents or legal guardians signed the Informed consent form Control Inclusion Criteria: * Minors aged 0 to 6 years or 6 to 12 years, hospitalized for assessment of severe respiratory syndrome except severe asthma * Minors need with his follow-up an bronchial endoscopy with realization of LBA and biopsies of bronchial mucosa * Social insurance affiliation, except AME * Parents or legal guardians signed the Informed consent form Patient Exclusion Criteria * Prematurity (\<37 weeks gestation) * Broncho-pulmonary dysplasia, immune deficits, non-Severe Asthma bronchopathies, cystic fibrosis, heart disease, ongoing biotherapy
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Severe asthma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Name: Hôpital Necker-Enfants Malades
Paris, 75015, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single injection tame severe asthma in fungal allergy?
- Could a simple exercise programme boost asthma remission?
- A two-step strategy: biologic drug may pave the way for immunotherapy in severe olive pollen asthma
- Could a biologic drug free severe asthma patients from High-Dose steroids?
- Scientists probe why tezepelumab doesn't stop all asthma attacks
- Smart inhalers track Fasenra's asthma control over full dosing cycle